Abstract
Breast cancer diagnosed at a young age is associated with a poor prognosis. It is possible that inadequate endocrine therapy for the youngest women contributes to their poorer prognosis. Data on optimal endocrine therapy selection as well as duration for premenopausal women are crucial. Recently published clinical trials including Australian Breast and Colorectal Cancer Study Group-12 (ABCSG-12), E-3193, and Suppression of Ovarian Function Trial (SOFT)/Tamoxifen and Exemestane Trial (TEXT) have shed light on the role of ovarian function suppression and aromatase inhibitors in premenopausal women. Additionally, optimal duration of endocrine therapy has been addressed in the recent Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) and Adjuvant Tamoxifen—To Offer More? (aTTom) trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
